TMS 2026: HSDD biopsychosocial approach, night sweats red flags, misread WHI data
The Menopause Society 2026 Annual Meeting highlighted new clinical trial data for the drug elinzanetant and discussed biopsychosocial approaches to treating hypoactive sexual desire disorder. Experts also addressed the management of vasomotor symptoms and the importance of distinguishing menopause from other medical conditions.
Why it matters
These findings provide updated clinical guidance and treatment options for menopause management, directly impacting patient care standards.
Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top expert interviews and coverage from The Menopause Society 2026 Annual Meeting (Tuesday, October 20, to Saturday, October 24, 2026, in San Diego, California) and click on each link to read and watch anything you may have missed.
Pooled OASIS data: 66.9% achieve ≥50% VMS reduction with elinzanetant
Elinzanetant reduced moderate-to-severe vasomotor symptom (VMS) frequency by ≥50% in 66.9% of US-postmenopausal participants, compared with 40.5% of those receiving placebo, from weeks 4 to 12, according to a pooled analysis of the phase 3 OASIS-1 (NCT05042362) and OASIS-2 (NCT05099159) trials presented at the meeting.
Click here for full study details.
A biopsychosocial approach to hypoactive sexual desire disorder
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in